Regulation is not AI's biggest hiccup—it is its credibility filter. UK regulated firms that treat compliance as a design feature, not a compliance checkbox, are already building systems that will survive both regulatory scrutiny and real-world use.
AI Governance  Trovix ReachLegal · Financial Services · Insurance · Accountancy

Fund managers are right to flag regulation as AI's next hurdle—but they are framing it backwards. The CNBC story treats regulatory oversight as an obstacle imposed on an industry that has thrived unencumbered. For UK legal, insurance, financial services and accountancy firms, this framing misses the point entirely. Regulation is not coming to slow AI down; it is coming to sort the competent implementations from the reckless ones. The FCA's Consumer Duty PS22/9, the SRA's Technology Code, the PRA's SS1/23 framework, and the ICO's GDPR enforcement escalation are not burdens on AI. They are guardrails that prevent mid-market firms from deploying systems that lose data, make unjustifiable decisions, or break audit trails. The firms panicking about 'regulatory hiccups' are the ones who have built AI stacks without governance from day one.

What this story reveals is that the financial markets have finally noticed what regulated professional services firms discovered months ago: you cannot move fast and break things when your client data and decision-making processes are subject to regulatory oversight. The EU AI Act, now operationalised across most of the financial sector, has already forced a recalibration. Generalist AI tools like Microsoft Copilot and some implementations of Harvey have hit walls because they lack the transparency, auditability and data isolation that the FRC ISA UK and Lloyd's Blueprint Two require. Firms that rushed to deploy large language models against unstructured documents without asking who owns the outputs, where the data lives, and how to prove the model wasn't hallucinating have discovered they cannot use those systems in regulated workflows. This is not regulation stifling innovation. This is regulation exposing which innovations were never viable.

Trovix's approach has always treated compliance as a design constraint, not an afterthought. Every feature in Trovix Watch exists because firms need to know when regulators change the rules—and why those changes matter for their deployed systems. Trovix Audit was built specifically because the question 'prove this AI decision is defensible' will only get more demanding, not less. We have watched competitors launch sleek interfaces backed by black-box models, marketed on speed and ease of deployment, only to watch clients realise those systems cannot be reconciled with their compliance obligations. The regulation is not stopping AI adoption. It is stopping bad AI adoption. Firms willing to build with governance structures from the start—provenance tracking, explainability layers, data residency controls, audit trails—are moving faster than those trying to retrofit compliance into systems designed for the consumer web.

If you run a mid-market law firm, insurer, wealth manager or accountancy practice, act on this now. Do not wait for your regulator to send a letter. Map what you have deployed: which systems touch client data, which systems make decisions that affect advice or pricing, which systems could create a regulatory breach if they fail. If your AI implementation cannot answer those questions clearly, it is not ready for regulated workflows. Start using Trovix Watch to track regulatory change velocity—it is accelerating, and compliance drift happens fast. If you are selecting AI tools for client intake or document automation, demand explainability and auditability guarantees in writing. Do not accept 'it works' as an answer. Demand 'prove it works and prove we can defend it.' The fund managers framing regulation as a hiccup are optimising for the wrong metric. You are not competing on speed to deployment. You are competing on the ability to deploy once and never have to explain to your regulator why you cannot.

Source: CNBC

Related Trovix product:

Trovix Reach →Book a demo →